Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

November 4, 2021 - … Financial Results for the Three Months Ended September 30, 2021 Vaxart ended the quarter with cash, cash equivalents …   6,838   Intangible assets, net     14,062       15,361   Total assets   $ 241,136     $ 152,582                   …   Operating lease liabilities     12,742       7,208   Total liabilities     36,188       29,178   Stockholders’ …
News

Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results

August 5, 2021 - … and marketable securities of $198.9 million as of June 30, 2021 SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2021 … net 5,808 6,838 Intangible assets, net 14,495 15,361 Total Assets $ 228,844 $ 152,582 Liabilities and … 14,927 14,929 Operating lease liabilities 6,154 7,208 Total liabilities 29,062 29,178 Stockholders' equity 199,782 …
News

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

July 7, 2021 - … in patients’ lives. I am hopeful that we can create modern antiviral treatments as we have with HIV, MERS and … in patients’ lives. I am hopeful that we can create modern antiviral treatments as we have with HIV, MERS and … in patients’ lives. I am hopeful that we can create modern antiviral treatments as we have with HIV, MERS and …
News

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

May 4, 2021 - … the optimal booster timing to maximize immunogenicity and total response of our oral norovirus vaccine candidate. … 1b Trial Design The Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old. Subjects will be … the optimal booster timing to maximize immunogenicity and total response of our oral norovirus vaccine candidate. …
News

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021 - … Ph.D., joined Vaxart as the SVP Quality. Dr. Kapoor brings 30 years of domestic and international experience with small … 6,838   Intangible assets, net   14,928     15,361        Total assets $ 205,866   $ 152,582                 … share,               basic and diluted   115,422,628       60,677,145   Source: Vaxart, Inc. Vaxart to advance three …
News

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021 - … Corporate: Strengthened the organization, bringing the total number of full-time equivalents to 49 people (including … Janssen which was substantially completed by September 30, 2020 . Research and development expenses were $8.6 … due to a settlement with Lonza for less than the total amount invoiced. No further restructuring charges or …
News

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

February 3, 2021 - … gastrointestinal in nature Including this study, a total of 495 subjects have now been dosed with our platform, … gastrointestinal in nature Including this study, a total of 495 subjects have now been dosed with our platform, … gastrointestinal in nature Including this study, a total of 495 subjects have now been dosed with our platform, …
Scroll to Top